Efficacy of immune checkpoint inhibitor therapy in egfr mutation-positive patients with nsclc and brain metastases who have failed egfr-tki therapy

HIGHLIGHTS

• who: Shujie Zhou from the Shanghai Pulmonary Hospital, China Huazhong University of Science and have published the Article: Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy, in the Journal: (JOURNAL) of 31/03/2022
• what: The authors found that among all ICI-containing therapies, ICI combined with chemotherapy had better CNS efficacy and it led to longer intracranial PFS and overall PFS compared to salvage chemotherapy, which suggests that this combined treatment strategy is effective and may be considered as a . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.